• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Improvement of severe pulmonary hypertension in a patient with SLE.

作者信息

Karmochkine M, Wechsler B, Godeau P, Brenot F, Jagot J L, Simonneau G

出版信息

Ann Rheum Dis. 1996 Aug;55(8):561-2. doi: 10.1136/ard.55.8.561.

DOI:10.1136/ard.55.8.561
PMID:8774190
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1010242/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eed9/1010242/bfe60e35db6f/annrheumd00353-0074-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eed9/1010242/bfe60e35db6f/annrheumd00353-0074-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eed9/1010242/bfe60e35db6f/annrheumd00353-0074-a.jpg

相似文献

1
Improvement of severe pulmonary hypertension in a patient with SLE.系统性红斑狼疮患者严重肺动脉高压的改善
Ann Rheum Dis. 1996 Aug;55(8):561-2. doi: 10.1136/ard.55.8.561.
2
Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome.采用免疫抑制、抗凝及血管扩张剂治疗系统性红斑狼疮合并继发性抗磷脂综合征所致肺动脉高压取得成功。
Lupus. 1998;7(7):495-7. doi: 10.1191/096120398678920442.
3
Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report.西地那非对系统性红斑狼疮所致继发性肺动脉高压有效吗？一例病例报告。
Clin Rheumatol. 2005 Nov;24(6):671-2. doi: 10.1007/s10067-005-1090-0. Epub 2005 Jun 11.
4
Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study.系统性红斑狼疮相关肺动脉高压可能得益于血管扩张剂治疗联合免疫抑制：一项观察性研究。
Rheumatology (Oxford). 2015 Sep;54(9):1673-9. doi: 10.1093/rheumatology/kev097. Epub 2015 Apr 29.
5
Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus.系统性红斑狼疮中对免疫抑制治疗有反应的肺动脉高压
Lupus. 1993 Dec;2(6):367-9. doi: 10.1177/096120339300200606.
6
Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus-associated pulmonary arterial hypertension.免疫抑制剂联合桥接血管扩张剂治疗重症红斑狼疮相关性肺动脉高压的疗效。
ESC Heart Fail. 2019 Dec;6(6):1322-1325. doi: 10.1002/ehf2.12507. Epub 2019 Sep 19.
7
Severe pulmonary arterial hypertension and cardiogenic shock in acute systemic lupus erythematosus.急性系统性红斑狼疮伴严重肺动脉高压和心源性休克
BMJ Case Rep. 2025 Jan 30;18(1):e262651. doi: 10.1136/bcr-2024-262651.
8
Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.狼疮和混合性结缔组织病相关肺动脉高压的免疫抑制治疗：23例回顾性分析
Arthritis Rheum. 2008 Feb;58(2):521-31. doi: 10.1002/art.23303.
9
Severe pulmonary arterial hypertension and massive ascites in a patient with systemic lupus erythematosus and secondary Sjogren's syndrome.系统性红斑狼疮和继发干燥综合征患者的严重肺动脉高压和大量腹水。
Lupus. 2021 Mar;30(3):510-513. doi: 10.1177/0961203320976982. Epub 2020 Dec 1.
10
Prevalence, patient characteristics and treatment patterns among systemic lupus erythematosus-pulmonary arterial hypertension patients in real-world clinical practice: A retrospective analysis of Medical Data Vision Database in Japan.在真实世界临床实践中系统性红斑狼疮-肺动脉高压患者的流行情况、患者特征和治疗模式：日本医疗数据视觉数据库的回顾性分析。
Mod Rheumatol. 2024 Jul 6;34(4):741-749. doi: 10.1093/mr/road090.

引用本文的文献

1
A very rare cause of pre-capillary pulmonary hypertension: The PAMI syndrome.毛细血管前性肺动脉高压的一种极其罕见的病因：PAMI综合征。
Pulm Circ. 2023 Oct 22;13(4):e12300. doi: 10.1002/pul2.12300. eCollection 2023 Oct.
2
Chronic intermittent hypobaric hypoxia attenuates monocrotaline-induced pulmonary arterial hypertension via modulating inflammation and suppressing NF-κB/p38 pathway.慢性间歇性低压缺氧通过调节炎症和抑制NF-κB/p38通路减轻野百合碱诱导的肺动脉高压。
Iran J Basic Med Sci. 2018 Mar;21(3):244-252. doi: 10.22038/ijbms.2018.25399.6280.
3
Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide.

本文引用的文献

1
Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide.系统性红斑狼疮患者的原发性肺动脉高压：环磷酰胺治疗后部分改善
J Rheumatol. 1993 Jun;20(6):1055-7.
2
Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus.系统性红斑狼疮患者肺动脉高压患病率及进展的五年随访研究
Am Heart J. 1995 Mar;129(3):510-5. doi: 10.1016/0002-8703(95)90278-3.
3
Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus.
糖皮质激素联合环磷酰胺治疗血管扩张剂抵抗的混合性结缔组织病相关肺动脉高压
Intern Med. 2017;56(4):445-448. doi: 10.2169/internalmedicine.56.7668. Epub 2017 Feb 15.
4
DNA Damage and Pulmonary Hypertension.DNA损伤与肺动脉高压
Int J Mol Sci. 2016 Jun 22;17(6):990. doi: 10.3390/ijms17060990.
5
Sildenafil Reduces Inflammation and Prevents Pulmonary Arterial Remodeling of the Monocrotaline - induced Disease in the Wistar Rats.西地那非可减轻炎症并预防Wistar大鼠中由野百合碱诱导疾病的肺动脉重塑。
Maedica (Bucur). 2012 Jun;7(2):109-16.
6
Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus.系统性硬皮病和系统性红斑狼疮相关肺动脉高压。
Eur Respir Rev. 2011 Dec;20(122):277-86. doi: 10.1183/09059180.00003811.
7
Treatment of pulmonary hypertension secondary to connective tissue diseases.结缔组织病继发肺动脉高压的治疗。
Thorax. 1999 Mar;54(3):273-7. doi: 10.1136/thx.54.3.273.
在系统性红斑狼疮期间，高剂量皮质类固醇可使毛细血管前性肺动脉高压显著改善。
J Rheumatol. 1994 Oct;21(10):1976-7.
4
Pulmonary hypertension in a lupus clinic: experience with twenty-four patients.狼疮诊所中的肺动脉高压：24例患者的经验
J Rheumatol. 1990 Oct;17(10):1292-8.
5
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.原发性肺动脉高压患者的生存情况。一项全国性前瞻性登记研究的结果。
Ann Intern Med. 1991 Sep 1;115(5):343-9. doi: 10.7326/0003-4819-115-5-343.
6
Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy.一名患有晚期肺动脉高压和混合性结缔组织病的患者接受免疫抑制治疗后的十年生存率。
J Rheumatol. 1992 Nov;19(11):1807-9.